Sökning: "Malmö Klinisk koagulationsmedicin"
Visar resultat 6 - 10 av 16 avhandlingar innehållade orden Malmö Klinisk koagulationsmedicin.
6. Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease
Sammanfattning : Haemophilia A (HA) is caused by defective synthesis of coagulation factor VIII(FVIII), which has serious effects on haemostasis; joints being the most common site of bleeding. The development of FVIII replacements has improved the situation for patients with haemophilia such that chronic arthropathy can be prevented, and life expectancy and the quality of life have increased. LÄS MER
7. Genetic Screening in Patients Suspected of Inherited Bleeding Disorders
Sammanfattning : Inherited bleeding disorders constitute a heterogeneous group of genetic diseases, affecting virtually all major components of the hemostatic system. The diagnostics are potentially complex, and a high proportion of patients remain without a conclusive diagnosis following work-up. LÄS MER
8. Bone Mineral Density in Haemophilila: A Treatment Outcome
Sammanfattning : Background: Osteoporosis is increasingly recognised as one of the major public health problems throughout the world and has massive socioeconomic implications. It has previously been shown that patients with severe haemophilia and not receiving any prophylactic treatment render a high risk of reduced bone density. LÄS MER
9. Genetic characterization of families with von Willebrand disease
Sammanfattning : von Willebrand disease (VWD) is the most common hereditary bleeding disorder. It is caused by quantitative and/or qualitative defects of the von Willebrand factor (VWF). The severity of the disease can vary considerably, as can the hereditary patterns. LÄS MER
10. Health-Related Quality of Life and Adherence in Haemophilia
Sammanfattning : Assessment of health-related quality of life (HRQoL) in haemophilia is important in order to provide information for clinical decision making and to verify the impact of haemophilia on patients and their families. Advances in haemophilia care and prophylactic treatment have improved HRQoL for the patients and where treatment is available, patients with haemophilia have almost reached the same life expectancy as the general population . LÄS MER